drugset / Trial / NCT03256422
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
Phase 3
Completed
640 enrolled
ANRS, Emerging Infectious Diseases
Institut National de la Santé Et de la Recherche Médicale, France · collabInstitut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The trial is an open-label, multicenter, prospective, randomized trial in 2 parallel groups, evaluating at W48, the non-inferiority of antiretroviral treatment taken 4 consecutive days a week versus continuous therapy, in HIV infected patients with controlled viral load for at least 12 months and stable antiretroviral treatment since 4 months.
Timeline
- Start
- 2017-09-07
- Primary completion
- 2019-08-06
- Completion
- 2020-03-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Abacavir | Other / unclassified | — | — |
| Background | Atazanavir | Other / unclassified | — | — |
| Background | Darunavir | Small molecule | — | — |
| Background | Dolutegravir | Other / unclassified | — | — |
| Background | Efavirenz | Other / unclassified | — | — |
| Background | Etravirine | Small molecule | — | — |
| Background | Lamivudine | Other / unclassified | — | — |
| Background | Lopinavir | Other / unclassified | — | — |
| Background | Raltegravir | Other / unclassified | — | — |
| Background | Rilpivirine | Small molecule | — | — |
| Background | Tenofovir | Small molecule | — | — |
| Background | elvitegravir/cobicistat | Unknown | — | — |
| Background | emtricitabine | Other / unclassified | — | — |